Bifogade filer
Number of shares and votes in Orexo
Kurs
-3,57%
Likviditet
0,76 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-05 | 08:00 | Bokslutskommuniké 2025 |
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-16 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-09 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2025-05-08 | - | Årsstämma |
| 2025-05-06 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | - | Bokslutskommuniké 2024 |
| 2024-12-18 | - | Extra Bolagsstämma 2025 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-17 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-29 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2024-04-26 | - | Årsstämma |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-10-26 | - | Extra Bolagsstämma 2023 |
| 2023-07-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-19 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2023-04-18 | - | Årsstämma |
| 2023-01-26 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-22 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2022-04-21 | - | Årsstämma |
| 2022-01-27 | - | Bokslutskommuniké 2021 |
| 2021-11-03 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-14 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2021-04-13 | - | Årsstämma |
| 2021-01-28 | - | Bokslutskommuniké 2020 |
| 2020-11-04 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-19 | - | Extra Bolagsstämma 2020 |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-17 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2020-04-16 | - | Årsstämma |
| 2020-01-30 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-11 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-02 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-14 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2019-04-11 | - | Årsstämma |
| 2019-01-30 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-11 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-13 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2018-04-12 | - | Årsstämma |
| 2018-01-25 | - | Bokslutskommuniké 2017 |
| 2017-10-19 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-11 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-20 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-07 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2017-04-06 | - | Årsstämma |
| 2017-01-26 | - | Bokslutskommuniké 2016 |
| 2016-10-20 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-12 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-21 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-18 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2016-04-15 | - | Årsstämma |
| 2016-01-28 | - | Bokslutskommuniké 2015 |
| 2015-10-22 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-10 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-23 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-16 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2015-04-15 | - | Årsstämma |
| 2015-01-29 | - | Bokslutskommuniké 2014 |
| 2014-10-22 | - | Analytiker möte 2014 |
| 2014-10-22 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-11 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-25 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-16 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2014-04-15 | - | Årsstämma |
| 2014-01-30 | - | Bokslutskommuniké 2013 |
| 2013-10-23 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-06 | - | Extra Bolagsstämma 2013 |
| 2013-07-12 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-26 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-12 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2013-04-11 | - | Årsstämma |
| 2013-03-13 | - | 15-7 2013 |
| 2013-01-31 | - | Bokslutskommuniké 2012 |
| 2012-10-25 | - | Kvartalsrapport 2012-Q3 |
| 2012-09-21 | - | 15-7 2012 |
| 2012-07-13 | - | Extra Bolagsstämma 2012 |
| 2012-07-12 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-03 | - | Kapitalmarknadsdag 2012 |
| 2012-04-27 | - | Kvartalsrapport 2012-Q1 |
| 2012-04-12 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2012-04-11 | - | Årsstämma |
| 2012-01-31 | - | Bokslutskommuniké 2011 |
| 2011-11-09 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-10 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-04 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-08 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2011-04-07 | - | Årsstämma |
| 2011-02-16 | - | Extra Bolagsstämma 2011 |
| 2011-02-16 | - | Bokslutskommuniké 2010 |
| 2010-11-10 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-20 | - | Kvartalsrapport 2010-Q2 |
| 2010-05-05 | - | Kvartalsrapport 2010-Q1 |
| 2010-04-22 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2010-04-21 | - | Årsstämma |
| 2010-02-17 | - | Bokslutskommuniké 2009 |
| 2009-11-10 | - | Kvartalsrapport 2009-Q3 |
| 2009-08-21 | - | Kvartalsrapport 2009-Q2 |
| 2009-05-06 | - | Kvartalsrapport 2009-Q1 |
| 2009-04-24 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2009-04-23 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, Sweden – June 30, 2025 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces that, during June 2025, the number of shares and votes in the company has changed as a result of the issue and repurchase of class C shares as announced on June 18, 2025. In total, the number of shares has increased by 2,446,000 class C shares and the votes have increased by 244,600.
Today, the last trading day of the month, there are in total 37,156,639 shares in Orexo - whereof 34,710,639 are ordinary shares with one vote per share and 2,446,000 are class C shares with one tenth of a vote per share. The total number of votes in the company is 34,955,239.
For further information contact:
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US.
For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
This information is information that Orexo AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-06-30 17:30 CEST.
Attachments
Number of shares and votes in Orexo